GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • American Association for Cancer Research (AACR)  (5)
  • 1
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 82, No. 6 ( 2022-03-15), p. 1098-1109
    Abstract: Preventing development of childhood B-cell acute lymphoblastic leukemia (B-ALL), a disease with devastating effects, is a longstanding and unsolved challenge. Heterozygous germline alterations in the PAX5 gene can lead to B-ALL upon accumulation of secondary mutations affecting the JAK/STAT signaling pathway. Preclinical studies have shown that this malignant transformation occurs only under immune stress such as exposure to infectious pathogens. Here we show in Pax5+/− mice that transient, early-life administration of clinically relevant doses of ruxolitinib, a JAK1/2 inhibitor, significantly mitigates the risk of B-ALL following exposure to infection; 1 of 29 animals treated with ruxolitinib developed B-ALL versus 8 of 34 untreated mice. Ruxolitinib treatment preferentially targeted Pax5+/− versus wild-type B-cell progenitors and exerted unique effects on the Pax5+/− B-cell progenitor transcriptional program. These findings provide the first in vivo evidence for a potential strategy to prevent B-ALL development. Significance: JAK/STAT inhibition suppresses tumorigenesis in a B-ALL–susceptible mouse model, presenting a novel approach to prevent B-ALL onset.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2022
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 78, No. 13_Supplement ( 2018-07-01), p. 5359-5359
    Abstract: Previous studies of rare germline variants in cancer has largely been limited to the coding regions of known predisposition genes. The TCGA PanCanAtlas Germline Working Group is analyzing germline predisposing variants of 10,389 cases in 33 cancer types. We deployed more than 121,000 virtual machines running for over 600,000 hours on the ISB Cancer Genome Cloud to conduct massively parallel variant calling and analyses, and the resulting data are shared with scientists across institutions worldwide. Carriers of the functional regulatory variants add on to the 8.9% of cases carrying known pathogenic variants. Burden analyses reveal enrichment of rare variants in the 3'UTR region of NHP2 and POLH. Further, we observed variants aggregating in conserved regions of selected microRNA families that are also affected by somatic mutations, including mir-17 and mir-29. We nominate regulatory variants by using GWAVA and FunSeq2 corroborated with their enrichment in cancer. The prioritized variants are then further evaluated by further co-occurrence of two-hit events and expression changes in their respective tumor samples. Finally, we examine ancestries, familial history and age at onset for carriers of these variants. Overall, we aim to discover and establish the role of regulatory germline variants in oncogenesis. Citation Format: Kuan-lin Huang, Amila Weerasinghe, Yige Wu, Wen-wei Liang, R. Jay Mashl, Sheila Reynolds, Kathleen E. Houlahan, Ninad Oak, The Cancer Genome Atlas, Alexander J. Lazar, Michael C. Wendel, Ekta Khurana, Sharon Plon, Feng Chen, Mark Gerstein, Ilya Shmulevich, Li Ding. Regulatory germline variants in 10,389 adult cancers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 5359.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2018
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    Online Resource
    Online Resource
    American Association for Cancer Research (AACR) ; 2015
    In:  Molecular Cancer Therapeutics Vol. 14, No. 12_Supplement_2 ( 2015-12-01), p. C154-C154
    In: Molecular Cancer Therapeutics, American Association for Cancer Research (AACR), Vol. 14, No. 12_Supplement_2 ( 2015-12-01), p. C154-C154
    Abstract: Several statistical tools have been developed to identify genes mutated at rates significantly higher than the background, indicative of positive selection, involving large sample cohort studies. However, studies involving relatively smaller sample sizes or single data-type genome wide analysis are inherently restricted due to their limited statistical power to identify low frequency genetic variation. We undertook integrated copy number, mutation and expression analyses of head and neck cancer cell lines assessing multiple levels of biological regulation in individual samples to enrich for driver events affected by two or more alterations. Besides identifying TP53, PTEN, HRAS and MET as major altered HNSCC hallmark genes, this analysis uncovered 34 novel candidate tumor suppressor and oncogenes altered by at least two types of alterations. Of these, we find a driver heterozygous truncating mutation in Nuclear receptor binding protein NRBP1, a pseudokinase, identical to that reported in other cancers and similar to activating mutant alleles in non-human model organisms. In addition to demonstrating the ability of integrated analyses to uncover biologically important genetic variation in relatively small datasets, we report for the first time, mutant NRBP1 is oncogenic when ectopically expressed in NIH 3T3 cells. We further show that knockdown of NRBP1 in oral carcinoma cell lines bearing such NRBP1 mutations inhibits transformation and survival. In over all, this approach could be of immense value for studies involving fewer or rare clinical specimen that are otherwise inherently restrictive due to the limited statistical power to detect alterations existing at lower frequency. Citation Format: Pratik Chandrani, Pawan Upadhyay, Prajish Iyer, Mayur Tanna, Madhur Shetty, Raghuram Venkata Gorantala, Ninad Oak, Ankita Singh, Rohan Chaubal, Manoj Ramteke, Sudeep Gupta, Amit Dutt. Integrated genomics approach to identify driver alterations. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2015 Nov 5-9; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr C154.
    Type of Medium: Online Resource
    ISSN: 1535-7163 , 1538-8514
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2015
    detail.hit.zdb_id: 2062135-8
    SSG: 12
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    Online Resource
    Online Resource
    American Association for Cancer Research (AACR) ; 2014
    In:  Cancer Research Vol. 74, No. 23_Supplement ( 2014-12-01), p. 01-01
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 74, No. 23_Supplement ( 2014-12-01), p. 01-01
    Abstract: Introduction: Short telomeres characterize a spectrum of disorders related to defects in telomere maintenance. The prototypic telomere biology disorder is dyskeratosis congenita (DC), a syndrome associated with specific mucocutaneous features in combination with a markedly increased risk for bone marrow failure, myelodysplastic syndrome (MDS), and acute myeloid leukemia (AML), among other cancers. Germline defects in a subset of telomere maintenance genes have been observed in cohorts of subjects with various hematologic malignancies, including AML. In the setting of defects in DNA repair, critical telomere shortening may result in genomic instability and subsequent malignant transformation. However, a more extensive evaluation of telomere biology and DNA repair genes in childhood AML has not been performed. We hypothesized that variants resulting in premature truncation or rare missense mutations would be identified in a pediatric AML cohort. Methods: Our patient population included 82 subjects diagnosed with AML or MDS at the Texas Children's Cancer Center, all between the ages of 0 and 18. DNA samples included 61 that were from initial AML diagnosis, 18 that were in AML remission, and 3 from individuals with MDS. The specimens were analyzed using a custom Ampliseq Ion Torrent platform comprised of 43 genes related to telomere maintenance and DNA repair. Results: Our preliminary analysis focused on 13 genes with the strongest association to a DC or AML/MDS clinical phenotype, including the nine genes currently recognized as DC-associated genes. In addition, for the purposes of this initial analysis we included only variants categorized as stoploss/stopgain mutations or frameshift insertions/deletions. After excluding variants found in HapMap controls, those with a MAF ≥ 1% as reported in dbSNP or ARIC, and those with unacceptably low coverage or quality reads, 87 variants remained of which 33 were unique. Sequence reads for all 87 underwent two distinct and independent reviews for verification, using Integrated Genomics Viewer (IGV), with discordant variants undergoing re-review. After eliminating those variants with consensus from both reviewers to be false positives, 33 samples from all three patient subpopulations demonstrated a total of 14 unique variants resulting in a stoploss/stopgain or frameshift mutation in the following genes: CTC1, RTEL1, RUNX1, TEP1, TERC, TERT, TINF2, and WRAP53. Three of the variants were described in dbSNP and the remaining 11 variants were novel. None of the variants were previously associated with DC-spectrum, AML, or MDS phenotype. Conclusions: Preliminary analysis indicates that a proportion of this pediatric AML/MDS cohort demonstrates rare and potentially deleterious stoploss/stopgain or frameshift mutations within a set of genes related to telomere maintenance and DNA repair. Further analysis of this data, including variants resulting in missense changes, may provide additional evidence supporting the utility of this platform in better understanding factors contributing to the development of AML and MDS. Citation Format: Maria Gramatges, Ninad Oak, David Wheeler, Deborah Ritter, Donna Muzny, Sharon Plon. Genetic variation within genes related to telomere maintenance and DNA repair in a cohort of pediatric acute myeloid leukemia (AML) subjects. [abstract]. In: Proceedings of the AACR Special Conference: Cancer Susceptibility and Cancer Susceptibility Syndromes; Jan 29-Feb 1, 2014; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(23 Suppl):Abstract nr 01. doi:10.1158/1538-7445.CANSUSC14-01
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2014
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 5
    In: Clinical Cancer Research, American Association for Cancer Research (AACR), Vol. 29, No. 7 ( 2023-04-03), p. 1243-1251
    Abstract: Clinical genomic sequencing of pediatric tumors is increasingly uncovering pathogenic variants in adult-onset cancer predisposition genes (aoCPG). Nevertheless, it remains poorly understood how often aoCPG variants are of germline origin and whether they influence tumor molecular profiles and/or clinical care. In this study, we examined the prevalence, spectrum, and impacts of aoCPG variants on tumor genomic features and patient management at our institution. Experimental Design: This is a retrospective study of 1,018 children with cancer who underwent clinical genomic sequencing of their tumors. Tumor genomic data were queried for pathogenic variants affecting 24 preselected aoCPGs. Available tumor whole-genome sequencing (WGS) data were evaluated for second hit mutations, loss of heterozygosity (LOH), DNA mutational signatures, and homologous recombination deficiency (HRD). Patients whose tumors harbored one or more pathogenic aoCPG variants underwent subsequent germline testing based on hereditary cancer evaluation and family or provider preference. Results: Thirty-three patients (3%) had tumors harboring pathogenic variants affecting one or more aoCPGs. Among 21 tumors with sufficient WGS sequencing data, six (29%) harbored a second hit or LOH affecting the remaining aoCPG allele with four of these six tumors (67%) also exhibiting a DNA mutational signature consistent with the altered aoCPG. Two additional tumors demonstrated HRD, of uncertain relation to the identified aoCPG variant. Twenty-one of 26 patients (81%) completing germline testing were positive for the aoCPG variant in the germline. All germline-positive patients were counseled regarding future cancer risks, surveillance, and risk-reducing measures. No patients had immediate cancer therapy changed due to aoCPG data. Conclusions: AoCPG variants are rare in pediatric tumors; however, many originate in the germline. Almost one third of tumor aoCPG variants examined exhibited a second hit and/or conferred an abnormal DNA mutational profile suggesting a role in tumor formation. aoCPG information aids in cancer risk prediction but is not commonly used to alter the treatment of pediatric cancers.
    Type of Medium: Online Resource
    ISSN: 1078-0432 , 1557-3265
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2023
    detail.hit.zdb_id: 1225457-5
    detail.hit.zdb_id: 2036787-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...